Patents Assigned to Leuven Research & Development VZW
-
Patent number: 7604952Abstract: A method having clinically sufficient degree of diagnostic accuracy for detecting the presence of coronary artery disease in a human patient from the general population and for distinguishing between the stages of the disease in that patient is disclosed. The stages are, first, the non-acute stage, which is either asymptomatic coronary artery disease or stable angina, second, the acute stage known as unstable angina, and, third, the acute stage known as acute myocardial infarction. The diseased state (as opposed to the non-diseased state) is indicated by the clinically significant presence of a first marker in a sample from the patient. The presence of one of the two acute stages, unstable angina or acute myocardial infarction, is indicated by the clinically significant presence of a second marker in a sample from the patient. The presence of the more severe acute stage known as acute myocardial infarction is indicated by the clinically significant presence of a third marker in a sample from the patient.Type: GrantFiled: January 16, 2007Date of Patent: October 20, 2009Assignee: Leuven Research & Development VZWInventors: Paul N. Holvoet, Désiré J. Collen
-
Patent number: 7390627Abstract: Immunoassays for malondialdehyde-modified low density lipoprotein (MDA-modified LDL) and oxidized low density lipoprotein (OxLDL), monoclonal antibodies (and the cell lines for them) for use in the assays, and a storage-stable standard (which may be used as a calibrator and/or control) are disclosed. MDA-modified LDL and OxLDL are implicated in atherosclerosis and its etiology.Type: GrantFiled: June 12, 2007Date of Patent: June 24, 2008Assignee: Leuven Research & Development VZWInventors: Paul Noel Holvoet, Désiré José Collen
-
Patent number: 7378250Abstract: Immunoassays for malondialdehyde-modified low density lipoprotein (MDA-modified LDL) and oxidized low density lipoprotein (OxLDL), monoclonal antibodies (and the cell lines for them) for use in the assays, and a storage-stable standard (which may be used as a calibrator and/or control) are disclosed. MDA-modified LDL and OxLDL are implicated in atherosclerosis and its etiology.Type: GrantFiled: May 7, 2007Date of Patent: May 27, 2008Assignee: Leuven Research & Development VZWInventors: Paul Noel Holvoet, Desire Jose Collen
-
Patent number: 7229775Abstract: Immunoassays for malondialdehyde-modified low density lipoprotein (MDA-modified LDL) and oxidized low density lipoprotein (OxLDL), monoclonal antibodies (and the cell lines for them) for use in the assays, and a storage-stable standard (which may be used as a calibrator and/or control) are disclosed. MDA-modified LDL and OxLDL are implicated in atherosclerosis and its etiology.Type: GrantFiled: March 17, 2004Date of Patent: June 12, 2007Assignee: Leuven Research & Development VZWInventors: Paul Noel Holvoet, Désiré José Collen
-
Patent number: 7229776Abstract: Immunoassays for malondialdehyde-modified low density lipoprotein (MDA-modified LDL) and oxidized low density lipoprotein (OxLDL), monoclonal antibodies (and the cell lines for them) for use in the assays, and a storage-stable standard (which may be used as a calibrator and/or control) are disclosed. MDA-modified LDL and OxLDL are implicated in atherosclerosis and its etiology.Type: GrantFiled: March 17, 2004Date of Patent: June 12, 2007Assignee: Leuven Research & Development VZWInventors: Paul Noel Holvoet, Désiré José Collen
-
Patent number: 7166469Abstract: A method having clinically sufficient degree of diagnostic accuracy for detecting the presence of coronary artery disease in a human patient from the general population and for distinguishing between the stages of the disease in that patient is disclosed. The stages are, first, the non-acute stage, which is either asymptomatic coronary artery disease or stable angina, second, the acute stage known as unstable angina, and, third, the acute stage known as acute myocardial infarction. The diseased state (as opposed to the non-diseased state) is indicated by the clinically significant presence of a first marker in a sample from the patient. The presence of one of the two acute stages, unstable angina or acute myocardial infarction, is indicated by the clinically significant presence of a second marker in a sample from the patient. The presence of the more severe acute stage known as acute myocardial infarction is indicated by the clinically significant presence of a third marker in a sample from the patient.Type: GrantFiled: June 18, 2002Date of Patent: January 23, 2007Assignee: Leuven Research & Development VZWInventors: Paul N. Holvoet, Désiré J. Collen
-
Patent number: 6902733Abstract: Methods for the identification, production and use of staphylokinase derivatives characterized by a reduced immunogenicity after administration in patients. The derivatives of the invention are obtained by preparing a DNA fragment comprising at least the part of the coding sequence of staphylokinase that provides for its biological activity; performing in vitro site-directed mutagenesis on the DNA fragment to replace one or more codons for wild-type amino acids by a codon for another amino acid; cloning the mutated DNA fragment in a suitable vector; transforming or transfecting a suitable host cell with the vector; culturing the host cell under conditions suitable for expressing the DNA fragment; and purifying the expressed staphylokinase derivative to homogeneity. Preferably the DNA fragment is a 453 bp EcoRI-HindIII fragment of the plasmid pMEX602sakB, (pMEX.Type: GrantFiled: November 30, 2000Date of Patent: June 7, 2005Assignees: Desire′ Jose′ Collen, Leuven Research & Development VZWInventor: Désire José Collen
-
Publication number: 20040175759Abstract: Immunoassays for malondialdehyde-modified low density lipoprotein (MDA-modified LDL) and oxidized low density lipoprotein (OxLDL), monoclonal antibodies (and the cell lines for them) for use in the assays, and a storage-stable standard (which may be used as a calibrator and/or control) are disclosed. MDA-modified LDL and OxLDL are implicated in atherosclerosis and its etiology.Type: ApplicationFiled: March 17, 2004Publication date: September 9, 2004Applicant: Leuven Research & Development VZWInventors: Paul Noel Holvoet, Desire Jose Collen
-
Patent number: 6727102Abstract: Immunoassays for malondialdehyde-modified low density lipprotein (MDA-modified LDL) and oxidized low density lipprotein (OxLDL), monoclonal antibodies (and the cell lines for them) for use in the assays, and a storage-stable standard (which may be used as a calibrator and/or control) are disclosed. MDA-modified LDL and OxLDL are implicated in atherosclerosis and its etiology.Type: GrantFiled: December 20, 1999Date of Patent: April 27, 2004Assignee: Leuven Research & Development VZWInventors: Paul Noel Holvoet, Désiré José Collen
-
Patent number: 6602509Abstract: The present invention is related to a compound for the prevention and/or the treatment of allergy consisting of: at least one allergen antigenic determinant which is recognized by a B cell or an antibody secreted by a B cell of a non-atopic individual to said allergen, and at least one antigenic determinant of an antigen different from said allergen which triggers T cell activation.Type: GrantFiled: July 29, 1999Date of Patent: August 5, 2003Assignee: Leuven Research & Development VZWInventors: Jean-Marie Saint-Remy, Marc Jacquemin
-
Publication number: 20030013127Abstract: A method having clinically sufficient degree of diagnostic accuracy for detecting the presence of coronary artery disease in a human patient from the general population and for distinguishing between the stages of the disease in that patient is disclosed. The stages are, first, the non-acute stage, which is either asymptomatic coronary artery disease or stable angina, second, the acute stage known as unstable angina, and, third, the acute stage known as acute myocardial infarction. The diseased state (as opposed to the non-diseased state) is indicated by the clinically significant presence of a first marker in a sample from the patient. The presence of one of the two acute stages, unstable angina or acute myocardial infarction, is indicated by the clinically significant presence of a second marker in a sample from the patient. The presence of the more severe acute stage known as acute myocardial infarction is indicated by the clinically significant presence of a third marker in a sample from the patient.Type: ApplicationFiled: June 18, 2002Publication date: January 16, 2003Applicant: LEUVEN RESEARCH & DEVELOPMENT VZWInventors: Paul N. Holvoet, Desire J. Collen
-
Patent number: 6398757Abstract: A catheter containing an inflatable balloon, which is at its periphery provided with hollow extensions that communicate between the outside of the balloon and the lumen of the catheter for use in the gene therapeutic treatment of local disorders by transfer of a desired gene to a target cell or tissue being part of or being located in the vicinity of a blood vessel. The catheter is preferably the Infiltrator® catheter.Type: GrantFiled: October 26, 1999Date of Patent: June 4, 2002Assignees: Leuven Research & Development VZW, Vlaams Interuniversitair Instituut voor BiotechnologieInventors: Olivier Henry Varenne, Désiré José Collen, Stefan Pierre Janssens
-
Publication number: 20010049112Abstract: A method having clinically sufficient degree of diagnostic accuracy for detecting the presence of coronary artery disease in a human patient from the general population and for distinguishing between the stages of the disease in that patient is disclosed. The stages are, first, the non-acute stage, which is either asymptomatic coronary artery disease or stable angina, second, the acute stage known as unstable angina, and, third, the acute stage known as acute myocardial infarction. The diseased state (as opposed to the non-diseased state) is indicated by the clinically significant presence of a first marker in a sample from the patient. The presence of one of the two acute stages, unstable angina or acute myocardial infarction, is indicated by the clinically significant presence of a second marker in a sample from the patient. The presence of the more severe acute stage known as acute myocardial infarction is indicated by the clinically significant presence of a third marker in a sample from the patient.Type: ApplicationFiled: July 16, 2001Publication date: December 6, 2001Applicant: Leuven Research & Development VZWInventors: Paul N. Holvoet, Desire J. Collen
-
Patent number: 6309888Abstract: A method having clinically sufficient degree of diagnostic accuracy for detecting the presence of coronary artery disease in a human patient from the general population and for distinguishing between the stages of the disease in that patient is disclosed. The stages are, first, the non-acute stage, which is either asymptomatic coronary artery disease or stable angina, second, the acute stage known as unstable angina, and, third, the acute stage known as acute myocardial infarction. The diseased state (as opposed to the non-diseased state) is indicated by the clinically significant presence of a first marker in a sample from the patient. The presence of one of the two acute stages, unstable angina or acute myocardial infarction, is indicated by the clinically significant presence of a second marker in a sample from the patient. The presence of the more severe acute stage known as acute myocardial infarction is indicated by the clinically significant presence of a third marker in a sample from the patient.Type: GrantFiled: September 4, 1998Date of Patent: October 30, 2001Assignee: Leuven Research & Development VZWInventors: Paul N. Holvoet, Désiré J. Collen
-
Patent number: 5951980Abstract: Methods for the identification, production and use of derivatives of the invention obtained by preparing a DNA fragment comprising at least the part of the coding sequence of staphylokinase that provides for its biological activity; performing in vitro site-directed mutagenesis on the DNA fragment to replace one or more codons for wild-type amino acids by a codon for another amino acid; cloning the mutated DNA fragment in a suitable vector; transforming or transfecting a suitable host cell with the vector; and culturing the host cell under conditions suitable for expressing the DNA fragment. Preferably the DNA fragment is a 453 bp EcoRI-HindIII fragment of the plasmid pMEX602sakB, the in vitro site-directed mutagenesis is performed by spliced overlap extension polymerase chain reaction and the mutated DNA fragment is expressed in E. coli strain TG1 or WK6.Type: GrantFiled: January 16, 1997Date of Patent: September 14, 1999Assignees: Leuven Research & Development VZW, Desire Jose CollenInventor: Desire Jose Collen
-
Patent number: 5695754Abstract: A method for producing the derivatives of the invention by preparing a DNA fragment comprising at least the part of the coding sequence of staphylokinase that provides for its biological activity; performing in vitro site-directed mutagenesis on the DNA fragment to replace one or more codons for wild-type amino acids by a codon for another amino acid; cloning the mutated DNA fragment in a suitable vector; transforming or transfecting a suitable host cell with the vector; and culturing the host cell under conditions suitable for expressing the DNA fragment. Preferably the DNA fragment is a 466 bp EcoRI-HINDIII fragment of the plasmid pMEX602SAK, the in vitro site-directed mutagenesis is performed by an oligonucleotide-directed mutagenesis system using the plasmid pMa/c and the repair deficient E. coli strain WK6MutS, and the mutated DNA fragment is cloned in E. coli strain-WK6.Type: GrantFiled: January 11, 1995Date of Patent: December 9, 1997Assignees: Leuven Research & Development VZW, Desire CollenInventor: Desire Collen
-
Patent number: 5174994Abstract: Plasminogen activators of the tissue-type and plasminogen activators of the urokinase-type appear to have a synergistic action in vivo when administered together as thrombolytic agents. Use in pharmaceutical compositions and in methods for the preparation and use thereof are set forth.Type: GrantFiled: July 21, 1989Date of Patent: December 29, 1992Assignee: Leuven Research & Development VZWInventor: Desire J. Collen
-
Patent number: 4752603Abstract: A new plasminogen activator which is very similar to the plasminogen activator from blood can be isolated in good amounts from the culture fluid of human melanoma cells.This new plasminogen activator has a strong thrombolytic effect and pharmaceutical compositions thereof may be used in the therapeutic treatment of thrombosis disorders.Type: GrantFiled: May 28, 1986Date of Patent: June 21, 1988Assignee: Leuven Research and Development VZWInventors: Desire J. Collen, Dingeman C. Rijken, Osamu Matsuo
-
Patent number: 4285739Abstract: Solid bodies of copper-zinc-aluminium alloys having beta-crystal structure are manufactured by a powder-metallurgic process. Starting with a powder comprising 10-40% by weight of Zn, 1-12% by weight of Al and the balance Cu, the solid bodies are formed by means of a cold compacting step, an optional hot compacting step and a hot extrusion step.Type: GrantFiled: December 21, 1978Date of Patent: August 25, 1981Assignee: Leuven Research and Development VZWInventors: Andre E. A. Deruyttere, Lucas J. A. E. Delaey, Etienne A. D. Aernoudt, Josef R. Roos
-
Patent number: 4167481Abstract: Several metal ions, such as mercury, cadmium, copper, zinc, nickel and cobalt, may be removed from waste waters and similar solutions by treating such solutions with a cation exchanger in the presence of a polyamine. A treatment with clay minerals such as bentonite or montmorillonite in the presence of tetraethylenepentamine is preferred. The solution may be first combined with polyamine and then contacted with the cation exchanger, but in a preferred embodiment, the polyamine and cation exchanger are combined first to form a solid adsorbent and then contacted with the solution.Type: GrantFiled: July 22, 1977Date of Patent: September 11, 1979Assignee: Leuven Research & Development VZWInventors: Adrien E. J. Cremers, Andre P. A. Maes, Paul G. L. Piegneur